Skip to main content
. 2023 Jan 16;13(1):e12221. doi: 10.1002/clt2.12221

FIGURE 1.

FIGURE 1

Dupilumab levels in tear fluid and serum. Severity of ocular surface disease (OSD) is based on the moment of tear fluid collection, and on the eye with the highest severity within a patient. Bold lines display the median. Differences were calculated with Mann‐Whitney U tests. (A), Tear fluid dupilumab at week 4 of dupilumab (n = 43). (B) Tear fluid dupilumab at week 28 of dupilumab (n = 44). (C) Serum dupilumab at week 4 of dupilumab (n = 42). (D) Serum dupilumab at week 28 of dupilumab (n = 41). (E) Tear fluid dupilumab at the additional ophthalmological examination which was scheduled due to development of OSD symptoms and/or worsening of ocular inflammation (onset OSD or worsening of pre‐existent OSD) (n = 17, 6 samples are missing). * Indicates statistical significance.